Data from EMA (European Medicines Agency) - Curated by EPG Health - Last updated 26 September 2019

Indication(s)

Nucala is indicated as an add-on treatment for severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older.

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Moderate to severe asthma

Moderate to severe asthma

Access the comprehensive Learning Zone for moderate to severe asthma. Containing details about pathophysiology, a complete overview of asthma and daily reports from ERS Congress 2019. 

Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis

Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive fibrotic interstitial lung disease that occurs mostly in older adults, is limited to the lungs and often displays a characteristic imaging and histological appearance. Find out how to diagnose IPF and the latest interventions available for patients living with this burden.

Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

View highlights from recent congresses presented in new expert videos with leading physicians.

+ 7 more

Load more

Related Content

More information

Category Value
Agency product number EMEA/H/C/003860
Orphan designation No
Date First Approved 02-12-2015
Type Medicinal product subject to restricted medical prescription
Marketing authorisation holder GlaxoSmithKline Trading Services
Warnings This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions